Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
about
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.Managing sarcoma: where have we come from and where are we going?Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts.Sarcoma-The standard-bearer in cancer discovery.Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
P2860
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@ast
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@en
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@nl
type
label
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@ast
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@en
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@nl
prefLabel
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@ast
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@en
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@nl
P2860
P3181
P356
P1433
P1476
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
@en
P2093
Demytra Mitsis
Valerie Francescutti
P2860
P304
P3181
P356
10.1155/2016/9757219
P407
P577
2016-01-01T00:00:00Z